After a recent announcement from Novo Nordisk I cleared my schedule to record this episode with Dr. Todd Hobbs, Chief Medical Officer for North America and Ken Inchausti, Senior Director of Corporate Communications. In this open discussion they share resources and cost saving programs, details about insulin production, insulin trials and what’s on the horizon for insulin therapies. I learned SO much about a drug I’ve been taking for decades!
After being rejected to join an insulin therapy clinical trial, I was determined to find someone who was able to participate. DDG’s newest team member, Cynthia Celt, connected the dots and hooked me up with Craig who shared his recent experience as a participant in a rather intense trial. Thank you Craig for temporarily donating your body to science to help fellow insulin dependent dia-peeps. Keep on trucking… jeeping you brave soul.
DreaMed Diabetes, a leader in AI solutions for personalized diabetes management and the company behind the first artificial pancreas technology recently launched Advisor Pro software. This software can analyze glucose and insulin data in seconds and advise on an optimal treatment plan including basal rate, carb ratio, insulin sensitivity factor, and personal management tips. The Advisor Pro also allows remote clinic visits and frequent titration changes.
Steady Health is the first full-service digital diabetes clinic in the US. Their services combine the power of continuous glucose monitors and the convenience of telemedicine to deliver a new type of care to patients. You can see an endocrinologist from home and get ongoing care and support from a team of diabetes specialists.
A few months ago, I received a heartfelt video message from a person I’d never met, and it had me and my friends and family in tears. It was exactly the boost I needed to keep going. Dr. Fox is one of the good guys – the doctor who truly cares about his patients and their sense of wellbeing after leaving his office. His holistic mind, body, spirit approach is one you rarely, if ever, see in the endocrine world. He has taken a chance by stepping out of the traditional medical community box and intends to make a much larger impact on the diabetes community with his programming and overall approach to treatment. Continue reading →
As a person with Type 1 diabetes, I’ve been frustrated in years past with the lack of advancement for the treatment of this disease. It wasn’t until about five years ago that I decided to stop complaining and take action. I asked myself the question – why aren’t things changing and what can I do to help? I did a bit of research and with the help of my regular physician, I was added to a list of diabetes related trials. I had no idea what I was in for, but knew it was something I had to do. Continue reading →